Friday, January 15, 2021
ADVT 
International

FDA approves first COVID-19 drug: antiviral remdesivir

Darpan News Desk The Canadian Press, 22 Oct, 2020
  • FDA approves first COVID-19 drug: antiviral remdesivir

U.S. regulators on Thursday approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given through an IV for patients needing hospitalization.

The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.

It had been authorized for use on an emergency basis since spring, and now becomes the first drug to win full Food and Drug Administration approval for treating COVID-19. President Donald Trump received it when he was sickened earlier this month.

Veklury is approved for people at least 12 years old and weighing at least 88 pounds (40 kilograms) who need hospitalization for their coronavirus infection. For patients younger than 12, the FDA will still allow the drug’s use in certain cases under its previous emergency authorization.

The drug works by inhibiting a substance the virus uses to make copies of itself. Certain tests are required before starting patients on it. And the label warns against using it with the malaria drug hydroxychloroquine, because that can curb its effectiveness.

“We now have enough knowledge and a growing set of tools to help fight COVID-19,” Gilead's chief medical officer, Dr. Merdad Parsey, said in a statement.

The drug is either approved or has temporary authorization in about 50 countries, he noted.

Its price has been controversial, given that no studies have found it improves survival. Last week, a large study led by the World Health Organization found the drug did not help hospitalized COVID-19 patients, but that study did not include a placebo group and was less rigorous than previous ones that found a benefit.

Gilead charges $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries, and $3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors.

Only one treatment — steroids such as dexamethasone — has been shown so far to cut the risk of dying of COVID-19. The FDA also has given emergency authorization to using the blood of survivors and two companies are currently seeking similar authorization for experimental antibody drugs.

MORE International ARTICLES

Extra safety scrutiny planned as virus vaccine worries grow

Extra safety scrutiny planned as virus vaccine worries grow

The poll from The Associated Press-NORC Center for Public Affairs Research found only 46% of Americans want a COVID-19 vaccine and another 29% are unsure.

Extra safety scrutiny planned as virus vaccine worries grow

Retiree checks to rise 1.3% in 2021 amid coronavirus fallout

Retiree checks to rise 1.3% in 2021 amid coronavirus fallout

The COLA affects the personal finances of about 1 in 5 Americans, including Social Security recipients, disabled veterans and federal retirees, some 70 million people in all.

Retiree checks to rise 1.3% in 2021 amid coronavirus fallout

AP-NORC poll: New angst for caregivers in time of COVID-19

AP-NORC poll: New angst for caregivers in time of COVID-19

The Associated Press-NORC Center for Public Affairs Research poll finds that 17% of Americans say they are providing ongoing caregiving, part of an informal volunteer corps.

AP-NORC poll: New angst for caregivers in time of COVID-19

Am I immune to the coronavirus if I’ve already had it?

Am I immune to the coronavirus if I’ve already had it?

Reinfection so far has been rare. The best known example: Researchers in Hong Kong said a man had mild COVID-19 and then months later was infected again but showed no symptoms.

Am I immune to the coronavirus if I’ve already had it?

Antibody drugs are no cure but seem promising for COVID-19

Antibody drugs are no cure but seem promising for COVID-19

Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines mimic an infection to spur antibody production.

Antibody drugs are no cure but seem promising for COVID-19

Lilly seeks emergency use of its antibody drug for COVID-19

Lilly seeks emergency use of its antibody drug for COVID-19

Eli Lilly and Company announced the partial results Wednesday in a news release; they have not yet been published or reviewed by independent scientists.

Lilly seeks emergency use of its antibody drug for COVID-19